Jane Street Group LLC trimmed its holdings in ABIOMED, Inc. (NASDAQ:ABMD) by 9.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,752 shares of the medical equipment provider’s stock after selling 404 shares during the period. Jane Street Group LLC’s holdings in ABIOMED were worth $633,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in ABMD. Koch Industries Inc. lifted its position in shares of ABIOMED by 40,431.3% in the second quarter. Koch Industries Inc. now owns 799,277 shares of the medical equipment provider’s stock valued at $794,000 after acquiring an additional 797,305 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of ABIOMED by 2,219.4% in the third quarter. Wells Fargo & Company MN now owns 364,427 shares of the medical equipment provider’s stock worth $61,443,000 after purchasing an additional 348,715 shares during the last quarter. Baillie Gifford & Co. increased its holdings in shares of ABIOMED by 17.9% in the second quarter. Baillie Gifford & Co. now owns 1,971,690 shares of the medical equipment provider’s stock worth $282,543,000 after purchasing an additional 299,255 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of ABIOMED by 99.8% in the third quarter. American Century Companies Inc. now owns 484,142 shares of the medical equipment provider’s stock worth $81,626,000 after purchasing an additional 241,868 shares during the last quarter. Finally, FMR LLC bought a new stake in shares of ABIOMED in the second quarter worth about $32,609,000. Institutional investors and hedge funds own 90.92% of the company’s stock.

Shares of ABIOMED, Inc. (NASDAQ ABMD) opened at $188.71 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.84 and a quick ratio of 5.20. ABIOMED, Inc. has a twelve month low of $103.53 and a twelve month high of $200.28. The stock has a market capitalization of $8,536.37, a PE ratio of 123.76, a PEG ratio of 2.57 and a beta of 0.15.

ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.16. ABIOMED had a return on equity of 13.89% and a net margin of 18.27%. The company had revenue of $132.80 million for the quarter, compared to analysts’ expectations of $131.18 million. During the same period in the previous year, the firm posted $0.20 earnings per share. The firm’s revenue for the quarter was up 28.9% on a year-over-year basis. research analysts anticipate that ABIOMED, Inc. will post 2.38 EPS for the current fiscal year.

In other ABIOMED news, Director Dorothy E. Puhy sold 6,364 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $179.08, for a total transaction of $1,139,665.12. Following the sale, the director now directly owns 39,532 shares of the company’s stock, valued at $7,079,390.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Michael G. Howley sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $178.64, for a total value of $1,786,400.00. Following the sale, the vice president now directly owns 56,757 shares in the company, valued at $10,139,070.48. The disclosure for this sale can be found here. Insiders have sold 27,646 shares of company stock worth $4,836,333 over the last three months. 7.00% of the stock is currently owned by insiders.

Several equities research analysts have recently issued reports on ABMD shares. Zacks Investment Research raised ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 target price on the stock in a report on Tuesday, November 7th. SunTrust Banks reaffirmed a “buy” rating and issued a $195.00 target price on shares of ABIOMED in a report on Wednesday, November 1st. Jefferies Group lifted their target price on ABIOMED from $175.00 to $208.00 and gave the stock a “buy” rating in a report on Friday, September 29th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $160.00 target price on shares of ABIOMED in a report on Tuesday, August 29th. Finally, BidaskClub cut ABIOMED from a “buy” rating to a “hold” rating in a report on Saturday, August 26th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. ABIOMED currently has a consensus rating of “Buy” and an average price target of $190.43.

WARNING: “ABIOMED, Inc. (ABMD) Shares Sold by Jane Street Group LLC” was published by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/12/16/abiomed-inc-abmd-shares-sold-by-jane-street-group-llc.html.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.